Transcript of Earning Conference Call of Q4FY2026.
KPL · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Kwality Pharmaceuticals delivered its highest-ever quarterly and annual revenues in FY26 with Q4 revenue of INR 157.1 crores (up 35.8% YoY) and full-year revenue of INR 503 crores (up 36% YoY). PAT grew 69% to INR 67 crores with margins expanding from 10.8% to 13.4%. Management guided for FY27 revenue of INR 650 crores and PAT of INR 100 crores (conservative estimate, possibly INR 700 crores), with FY28 targeting INR 800-850 crores at 28% EBITDA margins, and FY29 aiming for INR 1,000 crores at 30% EBITDA. Oncology contributed ~INR 100 crores in FY26, projected to reach INR 300 crores by FY29. The company is expanding into high-regulated markets (Germany registrations expected within 2 months) and Latin America, while improving cash conversion cycle from 208 to 170 days. Working capital stress from Middle East disruptions is being addressed with 40% of INR 60-70 crores stuck receivables already recovered.
Strong execution with margin expansion and multi-year guidance indicates sustainable growth trajectory. The stock could re-rate as management delivers on the INR 1,000 crores FY29 target, driven by regulated market entry and oncology expansion, though near-term working capital pressures from export markets remain a watch item.